Fatty acid-derived lipid mediators and blood platelet aggregation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 4-6, 2010, Pages 227-230

  Lagarde, M ^a   Chen, P ^a   Vericel E ^a   Guichardant, M ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONIC ACID; CD59 ANTIGEN; DOCOSAHEXAENOIC ACID; LIPOXYGENASE; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE; THROMBOXANE RECEPTOR;

ARTICLE; BIOLOGICAL ACTIVITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; FATTY ACID OXIDATION; HUMAN; IC 50; LIPID PEROXIDATION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; TARGET CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 77951976861     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.02.017     Document Type: Article

References (39)

1. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 1992, 63:F181-191. Review.
2. Sprecher H., VanRollins M., Sun F., Wyche A., Needleman P. Dihomo-prostaglandins and -thromboxane. A prostaglandin family from adrenic acid that may be preferentially synthesized in the kidney. J. Biol. Chem. 1982, 257:3912-3918.
3. Sugimoto Y., Narumiya S., Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 2000, 39:289-314. Review.
4. Coffa G., Schneider C., Brash A.R. A comprehensive model of positional and stereo control in lipoxygenases. Biochem. Biophys. Res. Commun. 2005, 388:87-92. Review.
5. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol. Res. 2004, 50:1-11. Review.
6. 450 epoxygenase pathway. J. Lipid Res. 2009, 50:S52-S56. Review.
7. Van Rollins M., Frade P.D., Carretero O.A. Oxidation of 5,8,11,14,17-eicosapentaenoic acid by hepatic and renal microsomes. Biochim. Biophys. Acta 1988, 966:133-149.
8. 450 4F3B: effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:169-177.
9. Catalá A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 2009, 157:1-11. Review.
10. Bacot S., Bernoud-Hubac N., Chantegrel B., Deshayes C., Doutheau A., Ponsin G., Lagarde M., Guichardant M. Evidence for in situ ethanolamine phospholipid adducts with hydroxy-alkenals. J. Lipid Res. 2007, 48:816-825.
11. Bacot S., Bernoud-Hubac N., Baddas N., Chantegrel B., Deshayes C., Doutheau A., Lagarde M., Guichardant M. Covalent binding of hydroxy-alkenals 4-HDDE, 4-HHE, and 4-HNE to ethanolamine phospholipid subclasses. J. Lipid Res. 2003, 44:917-926.
12. Tanito M., Brush R.S., Elliott M.H., Wicker L.D., Henry K.R., Anderson R.E. High levels of retinal membrane docosahexaenoic acid increase susceptibility to stress-induced degeneration. J. Lipid Res. 2009, 50:807-819.
13. Davies S.S., Amarnath V., Roberts L.J. Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway. Chem. Phys. Lipids 2004, 128:85-99. Review.
14. Bernoud-Hubac N., Alam D.A., Lefils J., Davies S.S., Amarnath V., Guichardant M., Roberts L.J., Lagarde M. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. Biochim. Biophys. Acta 2009, 1791:307-313.
15. Thoma I., Krischke M., Loeffler C., Mueller M.J. The isoprostanoid pathway in plants. Chem. Phys. Lipids 2004, 128:135-148. Review.
16. Comporti M., Signorini C., Arezzini B., Vecchio D., Monaco B., Gardi C. F2-isoprostanes are not just markers of oxidative stress. Free Radical Biol. Med. 2008, 44:247-256. Review.
17. Roberts L.J., Fessel J.P. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem. Phys. Lipids 2004, 128:173-186. Review.
18. Cracowski J.L., Durand T., Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol. Sci. 2002, 23:360-366. Review.
19. Hamberg M., Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc. Natl. Acad. Sci. USA 1974, 71:3400-3404.
20. Bryant R.W., Simon T.C., Bailey T.M. Role of glutathione peroxidase and hexose monophosphate shunt in the platelet lipoxygenase pathway. J. Biol. Chem. 1982, 257:14937-14943.
21. Lagarde M. Metabolism of fatty acids by platelets and the functions of various metabolites in mediating platelet function. Prog. Lipid Res. 1988, 27:135-152. Review.
22. Croset M., Lagarde M. Stereospecific inhibition of PGH2-induced platelet aggregation by lipoxygenase products of icosaenoic acids. Biochem. Biophys. Res. Commun. 1983, 112:878-883.
23. Fonlup P., Croset M., Lagarde M. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets. Thromb. Res. 1991, 63:239-248.
24. Croset M., Sala A., Folco G.C., Lagarde M. Inhibition by lipoxygenase products of TXA2-like responses of platelets and vascular smooth muscle 14-Hydroxy from 22:6n-3 is more potent than 12-HETE. Biochem. Pharmacol. 1988, 37:1275-1280.
25. Karanian J.W., Kim H.Y., Salem N. Inhibitory effects of n-6 and n-3 hydroxy fatty acids on thromboxane (U46619)-induced smooth muscle contraction. J. Pharmacol. Exp. Ther. 1994, 270:1105-1109.
26. McGregor L., Morazain R., Renaud S. Platelet functions and fatty acid composition of platelet phospholipids in spontaneously hypertensive rats fed saturated or polyunsaturated fats. Atherosclerosis 1981, 38:129-136.
27. Lagarde M., Burtin M., Sprecher H., Dechavanne M., Renaud S. Potentiating effect of 5,8,11-eicosatrienoic acid on human platelet aggregation. Lipids 1983, 18:291-294.
28. Lagarde M., Burtin M., Rigaud M., Sprecher H., Dechavanne M., Renaud S. Prostaglandin E2-like activity of 20:3n-9 platelet lipoxygenase end-product. FEBS Lett. 1985, 181:53-56.
29. Smith W.L. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr. Opin. Cell Biol. 2005, 17:174-182. Review.
30. Calzada C., Vericel E., Lagarde M. Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation. Biochem. J. 1997, 325:495-500.
31. Calzada C., Véricel E., Mitel B., Coulon L., Lagarde M. 12(S)-Hydroperoxy-eicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets. J. Lipid Res. 2001, 42:1467-1473.
32. Coulon L., Calzada C., Moulin P., Véricel E., Lagarde M. Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radical Biol. Med. 2003, 35:616-625.
33. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 2003, 278:14677-14687.
34. Serhan C.N., Gotlinger K., Hong S., Arita M. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 2004, 73:155-172. Review.
35. Dangi B., Oben M., Nauroth J.M., Teymourlouei M., Needham M., Raman K., Arterburn L.M. Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J. Biol. Chem. 2009, 284:14744-14759.
36. Arie A., Li P.L., Wang W., Tang W.X., Fredman G., Hong S., Gotlinger K.H., Serhan C.N. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 2005, 270:43079-43086.
37. Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101:8491-8496.
38. Butovich I.A. On the structure and synthesis of neuroprotectin D1, a novel anti-inflammatory compound of the docosahexaenoic acid family. J. Lipid Res. 2005, 465:2311-2314.
39. Chen P., Fenet B., Michaud S., Tomczyk N., Véricel E., Lagarde M., Guichardant M. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 2009, 583:3478-3484.